The field of apoptosis has expanded to include research in almost all subject areas of cell biology. Despite this growth, there are still many unanswered questions, some of which are fundamental to the development of therapeutic strategies. Most importantly, the underlying mechanisms involved in conferring specificity of apoptotic signals must be determined. This will allow the development of treatments to delete injured or transformed cells and minimize damage to other tissues. Such information is also necessary to combat degenerative diseases, to prevent critical loss of cells. In addition, it would be of therapeutic benefit to selectively induce apoptosis in specific cells where removal of unwanted cells is required (e.g. tumour cells in malignant tissue or inflammatory cells responsible for tissue damage in chronic inflammatory disease). Therefore we have to understand how the full complement of signalling pathways, and survival and apoptotic proteins determine the end effect of an apoptotic signal. Apoptotic cells are known to functionally influence phagocytes that ingest them, but little is known of the effect of apoptosis on neighbouring cells or of signals generated during the apoptotic process itself. Although the processes of mitosis and apoptosis would appear to 155
Introduction
The exponential growth in our knowledge of the biochemistry and cellular mechanisms of apoptosis has allowed development of new strategies for therapeutic treatment of disease. Since the realization in the early 1980s that apoptosis or programmed cell death is an important physiological process in multicellular organisms, research into the underlying molecular mechanisms, cellular alterations and physiological consequences has yielded tremendous insights into the full significance of this process in homoeostasis. Apoptosis plays a fundamental role in oncogenesis, development, inflammation and immune regulation; it is now clear that both the manner in which cells die and their subsequent recognition by neighbouring cells or phagocytes profoundly influence tissue integrity and generation of immune responses. It is therefore not surprising that defects in these processes underlie disease pathogenesis and developmental errors. Although we can now define pathways linking death-receptor signalling to caspase activation and changes in the mitochondrial membrane potential and we have a detailed understanding of the cell-surface membrane changes during apoptosis, there are still many facets of programmed cell death that remain ill-defined. The close association of celldeath regulation with signalling pathways and intracellular mechanisms for detecting cellular stress may give clues as to the origins of apoptotic mechanisms. In multicellular organisms, apoptosis represents a mechanism for deletion of cells that have accumulated genetic modification or DNA damage that threatens the existence of the whole organism. The overall frequency of tumours is below the levels that would be predicted given the rates of spontaneously arising mutations or those arising from genotoxic insults. It has been suggested that for a multicellular organism, cells are 'cheap' and that the default response to perturbation of cellular homoeostasis should be apoptosis. In vertebrates, excess cell production is critical for innate immune mechanisms, allowing 'disposable' cells (e.g. granulocytes) to be produced in large numbers in the fight against infectious organisms. Similarly, in the acquired immune response, cells with diverse receptor specificities can be generated and then those that are not required can be eliminated (e.g. cells that are autoreactive). Many intracellular pathogens or viruses interfere with homoeostatic mechanisms, thereby influencing apoptotic-effector pathways.
Whereas some pathogens have exploited these mechanisms for survival advantage, deletion of infected cells and maintenance of tissue integrity was clearly a driving force in the development of molecular pathways involved in cell death. This chapter aims to discuss some of the unanswered questions and speculate on the future goals of apoptosis research.
A matter of specificity
One of the most pressing problems yet to be solved in programmed cell death research, which would allow full therapeutic benefit to be realized, is the understanding of how and why defined apoptotic signals can kill one cell, but have no effect on another. At present, many therapeutic interventions will also inflict damage on bystander cells, resulting in complications and side effects when dealing with patients. Although genetic studies in Caenorhabditis elegans and other model organisms have allowed us to fit the key molecular regulators of apoptosis into a generalized model, there are additional levels of complexity associated with increased cellular diversity and tissue compartmentalization. Such levels of complexity are implicitly required in multicellular organisms. A simple apoptotic 'switch' would place unnecessary restrictions upon the development of complexity of multicellular organisms. Instead, multiple levels of regulation allow some cells to be deleted more readily, whereas cells with little capacity for proliferation must be protected from apoptosis. For example, some cell types lack caspases that are critical for apoptosis in C. elegans and there are distinct, tissuespecific profiles of pro-apoptotic and survival proteins. Furthermore, diverse patterns of receptor expression on different cell types may confer differential responses to apoptotic signals within a single organ or tissue. In addition, there may be interplay between pro-apoptotic and other intracellular signalling pathways that act to moderate the engagement of apoptotic effectors. This can be refined further by differential expression patterns and activation profiles of key signalling intermediates such that the repertoire of kinases, phosphatases, transcription factors and proteases that are produced in a particular cell confer additional flexibility of response. For example, TNF␣ (tumour necrosis factor ␣) can drive apoptosis via the TNF-receptor-induced assembly of a death-inducing signalling complex. However, activation of the transcription factor nuclear factor B can override the apoptotic signal via the production of specific survival proteins. Therefore cellular responses to specific mediators of apoptosis can be interpreted in the context of micro-environmental cues.
Induction of apoptosis in specific cells would therefore be beneficial in a number of diseases. For example, in cancer therapy, one of the greatest breakthroughs would be complete induction of tumour-cell death leaving no resistant cells that would allow evasion of anti-tumour therapy. Additionally, it would be of paramount importance that therapy to induce tumour cell apoptosis did not detrimentally affect survival of healthy cells and tissues. In inflammatory diseases, where a particular cell is believed to contribute to tissue damage, it may be desir-able to specifically eliminate the offending cell by apoptosis. For example, in the asthmatic lung, where oeosinophils and/or lymphocytes are found in abundance and probably contribute to disease progression, a good therapeutic strategy would be to direct drugs to induce apoptosis in these cells without influencing the structural cells (e.g. epithelial cells) of the lung. In addition, such therapy would have to ensure that cells induced to undergo apoptosis are recognized and efficiently removed by macrophages without eliciting an inflammatory response. Failure to do this would cause detrimental inflammation due to liberation of histotoxic products from apoptotic cells that had undergone secondary necrosis due to failed clearance [1] . Indeed, it is possible that anti-asthma drugs already in clinical use may be using these mechanisms: for example, glucocorticoids induce apoptosis of eosinophils (and lymphocytes) and simultaneously enhance macrophage clearance of these apoptotic cells. Conversely, in degenerative disease (e.g. Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis), we need to define the factors that will prevent programmed cell death or convert necrotic to apoptotic death. Thus it seems likely that defining the fine-tuning of the death pathways in a specific cell or tissue will allow identification of targets that would modulate cell death for therapeutic gain.
Signalling during apoptosis
It is widely accepted that apoptotic cells become functionally senescent, but the question of whether apoptotic cells are really 'inert' remains open. In inflammatory loci, programmed cell death means that clearance occurs before cells become necrotic and cause tissue damage. Phagocytosis of apoptotic corpses influences macrophages causing them to release cytokines with antiinflammatory properties, such as transforming growth factor ␤ and interleukin 10. In addition, there is evidence that macrophages can direct apoptosis of surrounding cells. Studies of macrophage-clearance mechanisms indicate that recognition of apoptotic cells requires specific changes on the surface of the cell undergoing apoptosis. Thus apoptotic cells trigger signals generating an anti-inflammatory phenotype in the ingesting phagocytes, whereas a proinflammatory profile occurs when the phagocyte ingests non-apoptotic entities (e.g. necrotic cells or opsonized particles) [2] . It has been suggested that phagocyte recognition of apoptotic cells may be determined by a lack of signalling via the adhesion molecule CD31 [3] . It is possible that viable cells remain in constant dialogue with their neighbours through molecules such as CD31, representing another important homoeostatic mechanism. However, the possibility that apoptotic cells are not 'inert' remains to be fully explored.
Recent evidence suggests that cells undergoing apoptosis produce signals that can change the behaviour of other cells. Activation of caspase-3 initiated the release of lysophosphatidylcholine from apoptotic cell membranes which then acted as a chemotactic factor for macrophages [4] . Whether apoptotic cells can influence the behaviour of other neighbouring cells is not known and repre-sents a novel facet of cell-death research that is ripe for development. The intersection of signalling pathways from cell-adhesion molecules and those that influence cell survival is another example of how micro-environmental cues can determine cell survival. Recent studies have revealed that tumour-cell resistance to chemotherapeutic agents may be determined by the repertoire of adhesion receptors that are engaged. Another example of this phenomenon is the recent report that PECAM-1 (platelet-endothelial cell adhesion molecule)/CD31 acts as a powerful inhibitor of apoptosis, inhibiting Bax-induced cytochrome c release from mitochondria [5] . Thus an alternative strategy for targeting tumour cell apoptosis may be to 'uncouple' adhesion signalling in combination with more traditional radiotherapy or chemotherapeutic drugs. Within tissues, cellular detachment from neighbouring cells or extracellular matrix may precede or accompany apoptosis, although the mechanisms involved are not known. One possibility is that disengagement of cellular adhesion associated with apoptosis may trigger proliferation or migration in those cells adjacent to the dying cell.
Apoptosis versus mitosis
Given the similarities between mitosis and apoptosis in terms of nuclear reorganization and organelle disassembly, the idea that apoptosis represented failed or aborted mitosis has been proposed. Whereas this view has lost favour over the years, new data would support the suggestion that proteins involved in cell-cycle control also have a role in the induction of apoptosis. Little is known of other potential functions of these cell-cycle proteins in addition to their role as 'checkpoints' that allow a cell to divide or act to inhibit proliferation. Cell division requires the activation of CDKs (cyclin-dependent kinases) by partner proteins called cyclins. Fas-induced death in Jurkat cells causes activation of CDK2 when caspase-3 cleaves the inhibitory kinase, Wee1 [6] , although this does not involve general activation of mitotic mechanisms. In cultured cortical neurons, proteasome inhibitors induce apoptotic cell death in a manner that is dependent upon CDK2, CDK4 and CDK6 activation [7] . In mouse mesangial cells, differential localization of active CDK2 and cyclin A during proliferation (nuclear) and apoptosis (cytoplasmic) suggests that the subcellular location of CDK2 is an important determinant of whether a cell divides or dies [8] . Increased CDK activity occurred before mitochondrial involvement and did not involve caspases. Furthermore, some cell-cycle proteins such as p21Cip/Waf1 and p27Kip1 are known caspase targets and, as such, their cleavage could lead to CDK2 activation [9] . The CDK inhibitor p21Cip/Waf1 protects some cells from p53-mediated apoptosis, but is pro-apoptotic in some systems and conditions [10] . Whether proteins involved in the cell cycle are able to interact with molecules identified in the classical pathway of programmed cell death during either the activation (mitochondrial) or execution (capsases) phases remains to be addressed. It is now emerging that cyclins have broader roles in regulation of cellular function and recent data suggest that integrin-dependent cell migration may require Cdc2/Cdk1 and cyclin D1 (see [11] for a commentary). Such diversity in the roles of cell-cycle proteins in a given cell type may provide additional novel targets for therapeutic intervention strategies. The links between the distinct processes of mitosis and apoptosis are further underlined by recent data demonstrating that caspases may also be involved in cell proliferation as well as cell death. Caspases 8 and 6 exhibit increased activity in B-cells treated with proliferative stimuli, and specific caspase inhibitors blocked B-cell division independently of apoptosis [12] . Similar results have also been reported for activated T-cells [13] . The mechanisms by which caspase activation can be uncoupled from the rest of the apoptotic execution pathways remains to be determined, and whether caspase activation is involved in other non-apoptotic cellular responses is not yet known. The extremely close relationship between the evolution of what would appear to be diametrically opposed processes of cell division and apoptosis may reflect the requirement for protection of the genome, with apoptosis representing the ultimate 'checkpoint' in cell division when DNA is damaged.
Our understanding of how complex systems develop is still poorperhaps the application of complex mathematical models will help us to understand the way in which organs in which there are repeating structural units formed from cells (e.g. lung, kidney and liver) or how development of vascular beds is achieved. This may be critical in understanding the response to tissue injury and for the therapeutic goal of restoration of tissue architecture.
Pathogen-mediated interventions
Researchers have long been aware that viral infection can modulate the apoptotic programme. Whether viruses have 'hijacked' control proteins as a way to manipulate host-cell survival to ensure completion of their replication cycle or whether the cellular repertoire of apoptotic proteins has evolved to combat viral infection is unknown. Many survival proteins have viral homologues which can act at almost any point in the cell death pathway (see [14] and references therein), which would ensure that replication occurs. Paradoxically, virus-induced cell death may also be advantageous, since apoptotic-body formation and phagocytic uptake by neighbouring cells facilitates the spread of viral progeny without causing activation of the immune response. A single virus may therefore be able to produce mediators that can either promote or inhibit cell death according to the phase of the viral life cycle that is active. For example, the HIV-1 protein Nef can increase expression of cell-surface TNF␣, Tat can increase the expression of CD95, while Vpr induces cell-cycle arrest as a prelude to the induction of apoptosis. Conversely, both Tat and Vpr have been reported to inhibit cell death by increasing Bcl-2 levels. Interestingly, viruses can also manipulate apoptosis through interference with cell-cycle proteins such as p53 and pRb/p107/p130 [15] . Examination of virus-cell interactions will undoubtedly lead to a more comprehensive understanding of the mechanisms that underlie regulation of apoptosis. This may represent a starting point for the development of novel approaches to manipulation of cell death for therapeutic gain in either degenerative conditions or diseases in which cellular proliferative responses are dysregulated.
Other pathogens such as protozoa and bacteria have also been shown to affect apoptotic pathways (see [16] and references therein). For example, an important aspect of the pathogenic capacity of Mycobacterium tuberculosis is survival within host macrophages by active inhibition of phagosome-lysosome fusion. Stimulation of the P 2 X 7 receptor on infected macrophages induces macrophage apoptosis, leading to phagosome-lysosome fusion and consequently killing of intracellular mycobacteria. Recent evidence suggests that ligation of Toll-like receptors may also lead to induction of macrophage apoptosis and killing of intracellular mycobacteria, although the cellular mechanism has yet to be elucidated. Definition of the regulatory mechanisms underlying macrophage apoptosis and macrophage ability to kill mycobacteria may also provide novel approaches for manipulation of disease. Whether we can use our knowledge of the control of apoptosis in eukaryotes to induce bacterial death as an alternative to antibiotics is an intriguing possibility that may be worthy of further exploration.
Implications for the future
Government statistics forecast that by 2020 at least 20% of the population will be over 65. With the incidence of cancer and degenerative diseases increasing markedly with age, the manipulation of programmed cell death as a therapeutic strategy has obvious benefits. Although our understanding of this process has greatly increased in the last few years, there are still many questions that require answers. The importance of this field cannot and should not be underestimated; it is now poised to reap the rewards of years of research in terms of possible medical advances. 
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